ASF1A and chronic myelogenous leukemia, BCR-ABL1 positive: Our work clarifies how ASF1A acts as a molecular switch to control the transformation from CML-CP to CML-BC and uncovers a novel mechanism of Notch signaling activation, thereby targeting ASF1A might represent a promising therapeutic approach and a biomarker to detect phase progression in CML patients.